

# Applied Clinical Pharmacokinetics

Third Edition

**Larry A. Bauer, PharmD**

*Professor  
Department of Pharmacy  
School of Pharmacy*

*Adjunct Professor  
Department of Laboratory Medicine  
School of Medicine  
University of Washington  
Seattle, Washington*

**Mc  
Graw  
Hill  
Education**

**Medical**

New York Chicago San Francisco Athens London Madrid Mexico City  
Milan New Delhi Singapore Sydney Toronto

## Applied Clinical Pharmacokinetics, 3<sup>rd</sup> edition

Copyright © 2014 by McGraw-Hill Education. All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

Previous editions copyright © 2008, 2001.

1 2 3 4 5 6 7 8 9 0 DOC/DOC 18 17 16 15 14

ISBN 978-0-07-179458-9

MHID 0-07-179458-1

This book was set in Times by Cenveo® Publisher Services.  
The editors were Michael Weitz and Christina M. Thomas.  
The production supervisor was Catherine Saggese  
Project management was provided by Vastavikta Sharma, Cenveo Publisher Services.  
RR Donnelley was printer and binder.

This book is printed on acid-free paper.

### Library of Congress Cataloging-in-Publication Data

Bauer, Larry A., author.

Applied clinical pharmacokinetics / by Larry A. Bauer.—Third edition.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-07-179458-9 (hardcover : alk. paper)—ISBN 0-07-179458-1

(hardcover : alk. paper)

I. Title.

[DNLM: 1. Pharmacokinetics. 2. Pharmaceutical Preparations—administration & dosage. QV 38]

RM301.5

615'.7—dc23

2013029778

International Edition ISBN 978-1-25-925141-2; MHID 1-25-925-141-1. Copyright © 2014. Exclusive rights by McGraw-Hill Education, for manufacture and export. This book cannot be re-exported from the country to which it is consigned by McGraw-Hill Education. The International Edition is not available in North America.

McGraw-Hill Education books are available at special quantity discounts to use premiums and sales promotions, or for use in corporate training programs. To contact a representative please visit the Contact Us pages at [www.mhprofessional.com](http://www.mhprofessional.com).

# Dedication

Third time's a charm . . . right? Through the planned and unexpected, the little things and the big things, the pleasant side trips and trying travails, family are what make it all worthwhile. Thank you (S.P.B., L.A.B., and L.E.B.) for all of your love and support that helped make the third edition a reality.

Thanks for the huge amount of support and assistance from my colleagues. You guys help each and every day, whether it is insight on a new drug interaction, discussion of an interesting patient case, or the latest sports scores: John R. Horn, Douglas J. Black, Lingtak-Neander Chan, Danny D. Shen, and, of course, Philip D. Hansten.

“It’s pretty far, but it doesn’t seem like it.”—Yogi Berra

—L.A.B.

# Contents

About the Author ix

Foreword x

*From Applied Clinical Pharmacokinetics,  
Second Edition* xi

*From Applied Clinical Pharmacokinetics,  
First Edition* xii

## I. Basic concepts

### 1. Clinical Pharmacokinetic and Pharmacodynamic Concepts 3

Introduction 3  
Linear Versus Nonlinear Pharmacokinetics 3  
Clearance 6  
Volume of distribution 14  
Half-life and Elimination Rate Constant 16  
Michaelis-Menten or Saturable Pharmacokinetics 19  
Bioavailability 20  
Problems 22  
Answers to Problems 23

### 2. Clinical Pharmacokinetic Equations and Calculations 27

Introduction 27  
One-Compartment Model Equations for Linear Pharmacokinetics 27  
Designing Individualized Dosage Regimens Using One-Compartment Model Equations 38  
Multicompartment Models 41  
Michaelis-Menten Equations for Saturable Pharmacokinetics 41  
Calculation of Clearance, Volume of Distribution, and Half-life in Pharmacokinetic Research Studies 42  
Problems 43  
Answers to Problems 44

### 3. Drug Dosing in Special Populations: Renal and Hepatic Disease, Dialysis, Heart Failure, Obesity, and Drug Interactions 49

Introduction 49  
Renal Disease 49

Hepatic Disease 56  
Heart Failure 64  
Dialysis 65  
Hemodialysis 67  
Hemofiltration 71  
Peritoneal Dialysis 73  
Obesity 74  
Drug Interactions 76  
Problems 79  
Answers to Problems 81

## II. Antibiotics

### 4. The Aminoglycoside Antibiotics 89

Introduction 89  
Therapeutic and Toxic Concentrations 89  
Clinical Monitoring Parameters 92  
Basic Clinical Pharmacokinetic Parameters 93  
Effects of Disease States and Conditions on Aminoglycoside Pharmacokinetics and Dosing 95  
Drug Interactions 100  
Initial Dosage Determination Methods 100  
Use of Aminoglycoside Serum Concentrations to Alter Dosages 121  
Bayesian Pharmacokinetic Computer Programs 146  
Dosing Strategies 149  
Special Dosing Considerations 150  
Problems 152  
Answers to Problems 156

### 5. Vancomycin 197

Introduction 197  
Therapeutic and Toxic Concentrations 197  
Clinical Monitoring Parameters 200  
Basic Clinical Pharmacokinetic Parameters 201

Effects of Disease States and Conditions on Vancomycin Pharmacokinetics and Dosing	202
Drug Interactions	205
Initial Dosage Determination Methods	205
Use of Vancomycin Serum Concentrations to Alter Dosages	224
Area Under the Curve Method	241
Bayesian Pharmacokinetic Computer Programs	244
Dosing Strategies	246
Problems	247
Answers to Problems	250

### III. Cardiovascular Agents

#### 6. Digoxin 293

Therapeutic and Toxic Concentrations	293
Clinical Monitoring Parameters	295
Basic Clinical Pharmacokinetic Parameters	296
Effects of Disease States and Conditions on Digoxin Pharmacokinetics and Dosing	296
Drug Interactions	299
Initial Dosage Determination Methods	300
Pharmacokinetic Dosing Method	301
Use of Digoxin Serum Concentrations to Alter Dosages	309
Bayesian Pharmacokinetic Computer Programs	313
Dosing Strategies	315
Special Dosing Considerations	316
Problems	320
Answers to Problems	322

#### 7. Lidocaine 339

Introduction	339
Therapeutic and Toxic Concentrations	339
Clinical Monitoring Parameters	342
Basic Clinical Pharmacokinetic Parameters	342
Effects of Disease States and Conditions on Lidocaine Pharmacokinetics and Dosing	343
Drug Interactions	347
Initial Dosage Determination Methods	347
Use of Lidocaine Serum Concentrations to Alter Doses	353
Bayesian Pharmacokinetic Computer Programs	357
Dosing Strategies	359
Use of Lidocaine Booster Doses to Immediately Increase Serum Concentrations	359
Problems	360
Answers to Problems	361

#### 8. Procainamide/*N*-acetyl Procainamide 373

Introduction	373
Therapeutic and Toxic Concentrations	373
Clinical Monitoring Parameters	375
Basic Clinical Pharmacokinetic Parameters	376
Effects of Disease States and Conditions on Procainamide Pharmacokinetics and Dosing	377
Drug Interactions	380
Initial Dosage Determination Methods	380
Use of Procainamide and <i>N</i> -Acetylprocainamide Serum Concentrations to Alter Doses	387
Chiou Method	393
Bayesian Pharmacokinetic Computer Programs	394
Use of Procainamide Booster Doses to Immediately Increase Serum Concentrations	396
Dosing Strategies	397
Conversion of Procainamide Doses From Intravenous to Oral Route of Administration	397
Problems	398
Answers to Problems	400

#### 9. Quinidine 415

Introduction	415
Therapeutic and Toxic Concentrations	415
Clinical Monitoring Parameters	416
Basic Clinical Pharmacokinetic Parameters	417
Effects of Disease States and Conditions on Quinidine Pharmacokinetics and Dosing	418
Drug Interactions	420
Initial Dosage Determination Methods	421
Use of Quinidine Serum Concentrations to Alter Doses	426
Dosing Strategies	432
Conversion of Quinidine Doses From One Salt Form to Another	433
Problems	434
Answers to Problems	435

### IV. Anticonvulsants

#### 10. Phenytoin/Fosphenytoin 447

Introduction	447
Therapeutic and Toxic Concentrations	449
Clinical Usefulness of Unbound Phenytoin Concentrations	450
Clinical Monitoring Parameters	453

Basic Clinical Pharmacokinetic Parameters	453
Impact of Altered Plasma Protein Binding on Phenytoin Pharmacokinetics	457
Effects of Disease States and Conditions on Pharmacokinetics and Dosing	458
Drug Interactions	460
Initial Dosage Determination Methods	462
Literature-Based Recommended Dosing	466
Use of Phenytoin Serum Concentrations to Alter Doses	468
Bayesian Pharmacokinetic Computer Programs	481
Dosing Strategies	483
Use of Phenytoin Booster Doses to Immediately Increase Serum Concentrations	483
Problems	485
Answers to Problems	486

## 11. Carbamazepine 503

Introduction	503
Therapeutic and Toxic Concentrations	503
Clinical Monitoring Parameters	506
Basic Clinical Pharmacokinetic Parameters	506
Effects of Disease States and Conditions on Pharmacokinetics and Dosing	508
Drug Interactions	509
Initial Dosage Determination Methods	510
Use of Carbamazepine Serum Concentrations to Alter Doses	511
Bayesian Pharmacokinetic Computer Programs	512
Problems	512
Answers to Problems	513

## 12. Valproic Acid 517

Introduction	517
Therapeutic and Toxic Concentrations	517
Clinical Monitoring Parameters	521
Basic Clinical Pharmacokinetic Parameters	521
Effects of Disease States and Conditions on Pharmacokinetics and Dosing	523
Drug Interactions	524
Initial Dosage Determination Methods	526
Use of Valproic Acid Serum Concentrations to Alter Doses	530
Pharmacokinetic Parameter Method	532
Bayesian Pharmacokinetic Computer Programs	534
Dosing Strategies	536
Problems	537
Answers to Problems	538

## 13. Phenobarbital/Primidone 549

Introduction	549
Therapeutic and Toxic Concentrations	549
Clinical Monitoring Parameters	551
Basic Clinical Pharmacokinetic Parameters	552
Effects of Disease States and Conditions on Pharmacokinetics and Dosing	552
Drug Interactions	554
Initial Dosage Determination Methods	554
Use of Phenobarbital and Primidone Serum Concentrations to Alter Doses	559
Bayesian Pharmacokinetic Computer Programs	562
Dosing Strategies	563
Problems	564
Answers to Problems	565

## 14. Ethosuximide 573

Introduction	573
Therapeutic and Toxic Concentrations	575
Clinical Monitoring Parameters	575
Basic Clinical Pharmacokinetic Parameters	576
Effects of Disease States and Conditions on Pharmacokinetics and Dosing	576
Drug Interactions	577
Initial Dosage Determination Methods	577
Use of Ethosuximide Serum Concentrations to Alter Doses	580
Bayesian Pharmacokinetic Computer Programs	583
Dosing Strategies	585
Problems	585
Answers to Problems	586

## 15. Lamotrigine 593

Introduction	593
Therapeutic and Toxic Concentrations	595
Clinical Monitoring Parameters	595
Basic Clinical Pharmacokinetic Parameters	596
Effects of Diseases and Conditions on Pharmacokinetics and Dosing	597
Drug Interactions	600
Initial Dosage Determination Methods	603
Use of Lamotrigine Serum Concentrations to Alter Doses	607
Selection of Appropriate Pharmacokinetic Model and Equations	608
Bayesian Pharmacokinetics Computer Programs	609
Special Dosing Considerations	610
Problems	610
Answers to Problems	611

**16. Levetiracetam 619**

Introduction 619  
 Therapeutic and Toxic Concentrations 621  
 Clinical Monitoring Parameters 621  
 Basic Clinical Pharmacokinetic Parameters 622  
 Effects of Diseases and Conditions on Pharmacokinetics and Dosing 625  
 Drug Interactions 627  
 Initial Dosage Determination Methods 628  
 Use of Levetiracetam Serum Concentrations to Alter Doses 633  
 Bayesian Pharmacokinetic Computer Programs 638  
 Dosing Strategies 639  
 Special Dosing Considerations 640  
 Problems 640  
 Answers to Problems 641

**17. Oxcarbazepine/Eslicarbazepine 653**

Introduction 653  
*Oxcarbazepine* 656  
 Therapeutic and Toxic Concentrations 656  
 Clinical Monitoring Parameters 656  
 Basic Clinical Pharmacokinetic Parameters 656  
 Effects of Disease States and Conditions on Pharmacokinetics and Dosing 658  
 Drug Interactions 660  
 Initial Dosage Determination Methods 661  
 Use of MHD Serum Concentrations to Alter Doses of Oxcarbazepine 664  
 Bayesian Pharmacokinetics Computer Programs 665  
*Eslicarbazepine* 666  
 Introduction 666  
 Therapeutic and Toxic Concentrations 666  
 Clinical Monitoring Parameters 667  
 Basic Clinical Pharmacokinetic Parameters 667  
 Effects of Disease States and Conditions on Pharmacokinetics and Dosing 668  
 Drug Interactions 670  
 Initial Dosage Determination Methods 671  
 Use of Serum Concentrations to Alter Doses of Eslicarbazepine 672  
 Bayesian Pharmacokinetics Computer Programs 674  
 Problems 674  
 Answers to Problems 675

**V. Immunosuppressants****18. Cyclosporine 685**

Introduction 685  
 Therapeutic and Toxic Concentrations 685

Clinical Monitoring Parameters 687  
 Basic Clinical Pharmacokinetic Parameters 688  
 Effects of Disease States and Conditions on Cyclosporine Pharmacokinetics and Dosing 690  
 Drug Interactions 690  
 Initial Dosage Determination Methods 691  
 Use of Cyclosporine Concentrations to Alter Doses 694  
 Bayesian Pharmacokinetic Computer Programs 699  
 Dosing Strategies 701  
 Problems 701  
 Answers to Problems 703

**19. Tacrolimus 713**

Introduction 713  
 Therapeutic and Toxic Concentrations 713  
 Clinical Monitoring Parameters 715  
 Basic Clinical Pharmacokinetic Parameters 716  
 Effects of Disease States and Conditions on Tacrolimus Pharmacokinetics and Dosing 717  
 Drug Interactions 717  
 Initial Dosage Determination Methods 718  
 Use of Tacrolimus Concentrations to Alter Doses 720  
 Bayesian Pharmacokinetic Computer Programs 724  
 Dosing Strategies 726  
 Problems 727  
 Answers to Problems 728

**20. Sirolimus 737**

Introduction 737  
 Therapeutic and Toxic Concentrations 737  
 Clinical Monitoring Parameters 739  
 Basic Clinical Pharmacokinetic Parameters 740  
 Effects of Disease States and Conditions on Sirolimus Pharmacokinetics and Dosing 741  
 Drug Interactions 744  
 Initial Dosage Determination Methods 745  
 Use of Sirolimus Concentrations to Alter Doses 749  
 Bayesian Pharmacokinetic Computer Programs 753  
 Dosing Strategies 754  
 Problems 754  
 Answers to Problems 756

**VI. Other Drugs**

**21. Lithium 767**

Introduction 767  
Therapeutic and Toxic Concentrations 767  
Clinical Monitoring Parameters 768  
Basic Clinical Pharmacokinetic Parameters 769  
Effects of Disease States and Conditions  
on Lithium Pharmacokinetics 770  
Drug Interactions 770  
Initial Dosage Determination Methods 771  
Use of Lithium Serum Concentrations to Alter  
Dosages 780  
Dosing Strategies 783  
Problems 784  
Answers to Problems 785

**22. Theophylline 797**

Introduction 797  
Therapeutic and Toxic Concentrations 797  
Clinical Monitoring Parameters 798

Basic Clinical Pharmacokinetic Parameters 800  
Effects of Disease States and Conditions  
on Theophylline Pharmacokinetics  
and Dosing 800  
Drug Interactions 803  
Initial Dosage Determination Methods 804  
Use of Theophylline Serum Concentrations  
to Alter Doses 812  
Chiou Method 818  
Bayesian Pharmacokinetic Computer  
Programs 820  
Dosing Strategies 822  
Use of Theophylline Booster Doses to Immediately  
Increase Serum Concentrations 822  
Conversion of Theophylline Doses  
From Intravenous to Oral Route  
of Administration 823  
Removal of Theophylline Body Stores  
in Management of Theophylline Overdose 824  
Problems 825  
Answers to Problems 826

Index 847



# About the Author

**Larry A. Bauer, PharmD**, is a Professor at the University of Washington School of Pharmacy and has been on the faculty since 1980. He also holds an adjunct appointment at the same rank in the Department of Laboratory Medicine where he is a toxicology consultant. He received a Bachelor of Science in Pharmacy degree (1977, Magna Cum Laude) from the University of Washington and a Doctor of Pharmacy degree (1980) from the University of Kentucky under the supervision of Dr. Robert Blouin. He also completed an ASHP-accredited hospital pharmacy residency (1980) specializing in clinical pharmacokinetics from A. B. Chandler Medical Center at the University of Kentucky under the preceptorship of Dr. Paul Parker. Dr. Bauer is a fellow of the American College of Clinical Pharmacology and the American College of Clinical Pharmacy.

**Dr. Bauer's** specialty area is in clinical pharmacokinetics, and he teaches courses and offers clinical clerkships in this area. His research interests include the pharmacokinetics and pharmacodynamics of drug interactions, the effects of liver disease and age on drug metabolism, and computer modeling of population pharmacokinetics. He has over 165 published research papers, abstracts, books and book chapters. Dr. Bauer is a member of several clinical pharmacology and clinical pharmacy professional organizations. He was Consulting Editor of *Clinical Pharmacy* (1981–1990), Field Editor of *ASHP Signal* (1981–1983), and a member of the Editorial Board of *Clinical Pharmacology and Therapeutics*. Recently, he completed an appointment to the Editorial Board of *Antimicrobial Agents and Chemotherapy* and, he reviews for many other scientific publications. Dr. Bauer has precepted three post-doctoral fellows in clinical pharmacokinetics who currently have faculty appointments in schools of pharmacy or positions in the pharmaceutical industry.

# Foreword

As a pharmacist for 36 years, I am rarely surprised about most things that happen in my professional life. However, I continue to be amazed by the depth and breadth of both the practice and research efforts in the area of therapeutic drug monitoring. As I write this, it is baseball season, so perhaps that eternal philosopher says it best:

“In theory, there is no difference between theory and practice. In practice, there is.”—Yogi Berra

Antibiotics usually take front-and-center attention in clinical pharmacokinetics. While the aminoglycosides continue to develop quietly, vancomycin is demanding more attention as pharmacokinetic/pharmacodynamic (PK/PD) relationships are uncovered and pathogen MICs push upward (short version: the bacteria are winning).

Immunosuppressants continue to be the number one category of monitored drugs in our health care system, and sirolimus makes its debut in this edition of the book. Of course, being a large transplant center contributes to this trend, but it is a rare clinician that doesn't encounter transplant patients and their medications on a routine basis.

While being a static area for quite some time, the next generation anticonvulsants are finally coming into their own. Updated treatment guidelines put these agents squarely in the spotlight, and the increase in serum concentration monitoring for these medications has been impressive. The challenge with these newer drugs is the role that therapeutic drug monitoring will play in their therapy because the concentration-response relationships are not as well defined for them compared to the older agents. Lamotrigine, levetiracetam, oxcarbazepine, and eslicarbazepine are included in this edition.

As for me, preparation for the fourth edition begins today.

Larry A. Bauer, PharmD  
May 17, 2014

# From *Applied Clinical Pharmacokinetics*, Second Edition

Upon beginning my thirtieth year as a pharmacist, the number of new approaches that continue to be developed for therapeutic drug monitoring impresses me. The second edition of *Applied Clinical Pharmacokinetics* includes new methods to dose immunosuppressants (2-hour postdose cyclosporine concentrations, area under the curve methods for cyclosporine and tacrolimus), and the elevation of what were new methods of dosing antibiotics to the mainstream (extended interval and area under the curve methods for aminoglycosides, trough-only monitoring for vancomycin). Other additions include more complete coverage of pediatric patients, dosing during hemoperfusion, an overview of methods preceding the initial and dosage adjustment sections, and a dosing strategies section that groups together initial and dosage adjustment techniques into a logical sequence. Of course, relevant sections, examples, problems, and references have been updated as needed for each chapter. However, one thing that remains unchanged is the general organization and philosophy of the book (please see the excerpt from the first edition following this section).

Bernard of Chartres used to say that we are like dwarfs on the shoulders of giants, so that we can see more than they, and things at a greater distance, not by virtue of any sharpness of sight on our part, or any physical distinction, but because we are carried high and raised up by their giant size.—in *Metalogicon* (1159 A.D.), by John of Salisbury.

Depending on one's point of view, the discipline of therapeutic drug monitoring is entering its fifth decade. Some brilliant scientists and practitioners who have made significant contributions to the area (and whose names are in the reference list or attached to the methods recommended in this text) and changed the lives of countless patients are no longer with us. I extend my humble thanks to all of these exceptional individuals for making things a little bit clearer and a lot easier for the rest of us.

Larry A. Bauer, PharmD  
June 2008

# From *Applied Clinical Pharmacokinetics*, First Edition

The structure of this book is uniform for each chapter and is derived from my lectures in clinical pharmacokinetics. The introduction, which consists of a brief discussion of the clinical pharmacology and mechanism of action for the drug, is followed by sections that describe the therapeutic concentration range and anticipated adverse effects for the drug as well as a general monitoring scheme for the agent. Clinical monitoring parameters for therapeutic response and toxicity and basic clinical pharmacokinetic parameters for the compound are discussed next. The next sections describe the effects of disease states and conditions on the pharmacokinetics and dosing of the drug, and drug interactions that may occur with concurrent use of other agents. Each chapter concludes with a comprehensive presentation (with examples) of various methods to compute initial drug doses and to modify drug therapy regimens using serum concentrations to adjust doses. All dosing methods used in this text are ones that are published in peer-reviewed literature. Additionally, they are techniques that I have personal clinical experience with and have produced acceptable results in my practice and clinical clerkships. Finally, problems (with solutions) are included for each chapter so that the various dosing methods can be practiced. The problems are made up of brief clinical vignettes which, given a brief background, request that initial doses be computed or that dosage regimens be modified using drug concentrations.

This text is meant to teach clinical pharmacokinetic and therapeutic drug monitoring techniques to all clinical practitioners regardless of professional background. Pharmacists, physicians, nurse practitioners, and physician assistants are among the individuals who could benefit from the text. With the advent of the almost-universal Doctor of Pharmacy degree in colleges of pharmacy, this book could be used in a pharmaceuticals, pharmacokinetics, therapeutics, or clinical pharmacy course sequence. It is also possible to use this textbook in a self-directed manner to teach oneself or review important concepts and techniques. Every effort was made to make the chapters “student-friendly.” Abbreviations are held to an absolute minimum. When abbreviations are used, they are defined near the place where they are used. Rather than using appendices, important information is repeated in each drug section so that readers do not need to jump from section to section for critical data. Multiple dosage computation and adjustment techniques for each drug, ranging from the simplest to the sophisticated, are presented. The easiest pharmacokinetic equations that produce accurate results are used in each instance.

It is my strong belief that clinical pharmacokinetics cannot be practiced in a vacuum. Individuals interested in using these dosing techniques for their patients must also be excellent clinical practitioners. Although it is true that “kinetics = dose,” clinicians must be able to select the best drug therapy among many choices and appropriately monitor patients for therapeutic response, adverse drug effects, potential drug interactions, disease states and conditions that alter drug dosage, and so on. Thus, it is not acceptable to simply suggest a dose and walk away from the patient, satisfied that the job has been done. It is my sincere hope that this book will help clinicians increase their knowledge in the area of therapeutic drug monitoring and improve care to their patients.

Larry A. Bauer, PharmD  
May 17, 2014